The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3535-3543

  Barrera, Borja ^a   Otero, Jon A ^a   Egido, Estefanía ^a,b   Prieto, Julio G ^a   Seelig, Anna ^b   Álvarez, Ana I ^a   Merino, Gracia ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; DANOFLOXACIN; MITOXANTRONE; NITROFURANTOIN; SALAZOSULFAPYRIDINE; TRICLABENDAZOLE; TRICLABENDAZOLE SULFONE; TRICLABENDAZOLE SULFOXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; FEMALE; HUMAN; MALE; MEMBRANE TRANSPORT; MILK; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTHELMINTICS; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; SULFOXIDES;

EID: 84862510977     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06345-11     Document Type: Article

References (36)

1. Aanismaa P, Seelig A. 2007. P-glycoprotein kinetics measured in plasma membrane vesicles and living cells. Biochemistry 46:3394-3404.
2. Breedveld P, et al. 2005. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65:2577-2582.
3. Breedveld P, et al. 2004. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64:5804-5811.
4. Dupuy J, Alvinerie M, Menez C, Lespine A. 2010. Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells. Chem. Biol. Interact. 186:280-286.
5. El-Tantawy WH, Salem HF, Mohammed Safwat NA. 2007. Effect of Fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects. Pharm. World Sci. 29:190-198.
6. Fairweather I. 2009. Triclabendazole progress report, 2005-2009: an advancement of learning? J. Helminthol. 83:139-150.
7. Fairweather I, Boray JC. 1999. Fasciolicides: efficacy, actions, resistance and its management. Vet. J. 158:81-112.
8. Giacomini KM, et al. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9:215-236.
9. Glavinas H, et al. 2007. ABCG2 (breast cancer resistance protein/ mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab. Dispos. 35:1533-1542.
10. Hennessy DR, Lacey E, Steel JW, Prichard RK. 1987. The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol. Ther. 10:64-72.
11. Jonker JW, et al. 2005. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11:127-129.
12. Jonker JW, et al. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92:1651-1656.
13. Kita T, et al. 2001. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol. Pharm. Bull. 24:1176-1180.
14. Kruijtzer CM, et al. 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20:2943-2950.
15. Lifschitz A, Virkel G, Ballent M, Sallovitz J, Lanusse C. 2009. Combined use of ivermectin and triclabendazole in sheep: in vitro and in vivo characterisation of their pharmacological interaction. Vet. J. 182:261-268.
16. Litman T, Zeuthen T, Skovsgaard T, Stein WD. 1997. Competitive, non-competitive and cooperative interactions between substrates of Pglycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1361:169-176.
17. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. 2007. Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927-941.
18. Merino G, et al. 2006. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab. Dispos. 34:690-695.
19. Merino G, et al. 2005. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab. Dispos. 33:614-618.
20. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. 2005. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol. 67:1758-1764.
21. Merino G, et al. 2010. In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice. Pharm. Res. 27:2098-2105.
22. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. 2009. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev. 61:26-33.
23. Pavek P, et al. 2005. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl- 6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312:144-152.
24. Perez M, et al. 2009. In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem. Biol. Interact. 180:106-112.
25. Perez M, et al. 2009. Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J. Vet. Pharmacol. Ther. 32:498-502.
26. Real R, et al. 2011. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin. J. Vet. Pharmacol. Ther. 34:313-321.
27. Seelig A. 2007. The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J. Mol. Neurosci. 33:32-41.
28. Shukla S, Ohnuma S, Ambudkar SV. 2011. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr. Drug Targets 12:621-630.
29. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5:219-234.
30. Tang SC, et al. 2012. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int. J. Cancer 130:223-233.
31. van Herwaarden AE, Schinkel AH. 2006. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol. Sci. 27:10-16.
32. van Herwaarden AE, et al. 2006. Breast cancer resistance protein (Bcrp1/ Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123-130.
33. Wang L, Leggas M, Goswami M, Empey PE, McNamara PJ. 2008. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9, 10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk. Drug Metab. Dispos. 36:2591-2596.
34. Weiss J, et al. 2007. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 59:238-245.
35. Zaher H, et al. 2006. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm. 3:55-61.
36. Zhou L, et al. 2008. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric- Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol. Pharmacol. 73:949-959.